Pentostatin (2′-Deoxycoformycin, dCF) in Patients with low-grade (B-T-Cell) and intermediate- and high-grade (T-Cell) malignant lymphomas: Phase II Study of the EORTC early clinical trials group

Oncology (Switzerland)

Volumn 53, Issue 2, 1996, Pages 163-168

  Monfardini, S ^a   Sorio, R ^a   Cavalli, F ^b   Cerny, T H ^c   Glabbeked, M Van ^d   Kaye, S ^e   Smith, J J ^f  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b City Hospital   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Malignant lymphomas; Pentostatin

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; PENTOSTATIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG FEVER; DRUG TOLERANCE; HODGKIN DISEASE; HUMAN; INJECTION SITE; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LEUKOPENIA; LUNG TOXICITY; MOUTH DISEASE; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SKIN TOXICITY; T CELL LYMPHOMA; VOMITING;

ADULT; AGED; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PENTOSTATIN; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0029869521     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227554     Document Type: Article

References (25)

1. Agarwal RP, Speclor T, Parks RH Jr: Tight-binding inhibitors. IV. Inhibitions of adenosine deaminases by various inhibitors. Biochem Pharmacol 1977:26:359.
2. Smyth JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG: The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin. Cancer Chemother Pharmacol 1980:5:93.
3. Woo PWK, Dion HW, Hange SM, Dahl LF, Durham LJ: A novel adenosine and araA deaminase inhibitor, (R)-3-(2-dcoxy-β-eryth-ropento-furanosyl)-3.6.7.8-tetrahydroimidazo (4.5-d) (1.3) diazepin-8-d. J Heterocyclic Chcm 1974:641.
4. Coleman MS, Greenwood MF, Hutton JJ, Holland P, Lampkin B, Krill C, Kastelic JE: Adenosine deaminase, terminal dcoxynucleotidc transferase (TdT) and cell surface markers in childhood acute leukemia. Blood 1978;52: 1125.
5. Giblett ER, Anderson JE, Cohen F, Pollara B, Mcuwissen HJ: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972;ii: 1067.
6. Grever MR, Bisaccia E, Scarborough DA, Metz EN, Ncidhart JA: An investigation of 2'-dcoxy-coformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983;61:279-282.
7. O’Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, Cheson BD, Hoth DF: 2'-Deoxyco-formycin (pcntostatin) for lymphoid malignancies: Rational development of an active new drug. Ann Intern Med 1988:108:733-743.
8. Ho AD, Gancshaguru K, Knauf WU, Dietz G, Trede I, Hunstein W, Hoffbrand AV: Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo. Blood 1988; 72:1884-1890.
9. Kanofsky JR, Roth DG, Smyth JF, Baron JM, Sweet DL, Ultman JE: Treatment of lymphoid malignancies with 2'-deoxycoformycin: A pilot study. Am J Clin Oncol 1982;5:179-183.
10. Major PP, Agarwal RP, Kufe DW: Deoxycoformycin: Neurological toxicity. Cancer Chemother Pharmacol 1981;5:193-196.
11. Grever MR, Leiby JM, Kraut EH, Wilson HE, Ncidhart JA, Wall RL, Balcerzak SP: Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985;3:1196-1201.
12. World Health Organization (WHO): Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva. 1979.
13. Hryniuck WM: The importance of dose intensity in the outcome of chemotherapy; in De Vita VT. Heilman S. Rosenberg S (cds): Important Advances in Oncology. Philadelphia. Lip-pincott, 1988. pp 121-141.
14. Kaplan EL, Meier P: Nonparamctric estimation from incomplete observations. JASA 1958:53:457-481.
15. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of new chemotherapeutic agents. J Chronic Dis 1961; 13:346-353.
16. Smyth JF, Prentice HG, Proctor S, Hoflbrand AV: Deoxycoformycin in the treatment of leukaemia and lymphomas. Ann NY Aead Sci 1985;451:123-128.
17. Cummings FJ, Kim K, Nciman RS, Comis RL, Oken MM, Weitzman SA, Mann RB. O'Connell MJ: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9:565-571.
18. Duggan DB, Anderson JR, Dillman R, Case D, Gottlieb AJ: 2'-Deoyxcoformycin (pentostatin) for refractory non-Hodgkin’s lymphoma: A CALGB phase II study. Med Pediatr Oncol 1990;18:203-206.
19. Dcardcn C, Catovsky D: Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990:62:4-5.
20. Mcrciccaq J, Matutes E, Dearden C, MacLcn-nan K, Catovsky D: The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12:2588-2593.
21. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr. Rodriguez MA, Plunkett WK, Keating MJ: Phase II trial of lludarabinc phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-794.
22. Savcn A, Piro LD: 2-Chlorodeoxyadenosinc: A new nucleoside agent effective in treatment of lymphoid malignancies. I-euk Lymphoma 1993; 10(S):43-49.
23. Hoffman M, Tallman MS, Hamikian D, Jan-son D, Hogan D, Variakogis D, Kuzcl T. Gordon LI, Rai K: 2-ChIorodcoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:788-792.
24. Höchster H, Cassilcth P: Fludarabinc phosphate therapy of non-Hodgkin's lymphomas. Semin Oncof 1990; 17(S8):63-65.
25. Grem JL, King SA, Chun HG, Grever MR: Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy. Am J Hcmatol 1991:38:245-247.